[1] |
YANG Xuyun, SUN Yang, TIAN Chunhua, HU Zengyao.
A National Pharmacovigilance Management System in a New Era
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(3): 276-281.
|
[2] |
SUN Yixin, WANG Chen, YU Yuelin, GUO Peng, NIE Xiaolu.
Safety Surveillance for Vaccine-Induced Immune Thrombotic Thrombocytopenia: a Systematic Review
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(1): 29-36.
|
[3] |
HOU Tiantian, WANG Xudong, YANG Ping, ZHOU Pengbo, QIN Chao, HUANG Ying, WANG Ailing, GENG Xingchao, ZHOU Xiaobing, LIU Defang.
Biodistribution of Therapeutic DNA Vaccines in Mice
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(1): 58-66.
|
[4] |
XIA Lanfang, LI Keli, WANG Lei, LI Yan, WANG Huaqing.
Impact of comparator selection on signal detection in adverse events following immunization in China
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(7): 798-804.
|
[5] |
LIU Yan, AN Jing, JIAO Yongzhuo, LIANG Xuefeng, ZHANG Xiaoshu.
Simple febrile seizures within 30 days of vaccination with the measles, mumps and rubella combined attenuated live vaccine in U-12 children in the real world
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(7): 805-810.
|
[6] |
NIE Xiaolu, MA Jingyao, SUN Feng, ZHAN Siyan.
Pathogenesis and diagnosis of drug-induced thrombocytopenia
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(7): 829-835.
|
[7] |
WU Yi, HE Jinyang, WANG Xiaojian, ZhOU Xiaozhu, LIU Ranjia, GUO Mingxing, ZHAO Ying, DAI Wendi, CUI Xiangli.
Adverse events of COVID-19 vaccination in recipients of liver and kidney transplant based on US VAERS database
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(5): 572-579.
|
[8] |
LIU Jie, ZHANG Jianmin, ZHANG Xiaomeng, LIU Fang, SONG Yuan, ZHONG Xuli.
Management of risks to pediatric medications based on drug instructions of Chinese patent medicines in a hospital
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(4): 422-427.
|
[9] |
MA Meiying, ZHAO Xiaopei, ZHANG Mengyao, HU Yilin.
Drug traceability coding system in China
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 167-172.
|
[10] |
GAO Xu, PENG Jin’e, LI Xingwang, ZHANG Wei.
Recent research of antiviral drugs and vaccines for Mpox
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 111-116.
|
[11] |
YUAN Sisi, WANG Guangyan, LI Yifan, LI Ruilian, DU Boran, FENG Xin.
Safety-related risk factors in clinical management of narcotics and psychotropic substances via failure mode and effect analysis
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1027-1030.
|
[12] |
ZHU Yuanchao, ZHANG Yatong, HU Xin.
Principles and measures of medication risk management in the elderly
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1031-1034.
|
[13] |
ZI Wenrui, YANG Qiuyue, SU Jun, XIE Jiang'an.
The research development of inoculation safety associated with licensed HPV vaccines in China
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(3): 311-316.
|
[14] |
ZHAO Huanhuan, SONG Jiawei, LIU Jinguang, HUANG Minghui.
One case of nephrotic syndrome caused by rabies vaccine in a 5-year-old child
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(11): 1303-1305.
|
[15] |
WU Yunxiao, YU Yuelin, WANG Shengfeng, SUN Feng, MENG Ruogu, ZHAN Siyan.
Suitability assessment of real-world data in active post-marketing surveillance of vaccine safety
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(10): 1081-1089.
|